hrcak mascot   Srce   HID

Libri Oncologici : Croatian Journal of Oncology, Vol. 47 No. 2-3, 2019.

Izvorni znanstveni članak
https://doi.org/10.20471/LO.2019.47.02-03.09

Rezultati liječenja bolesnika s metastatskim rakom bubrega nivolumabom – donacijskim programom na ime bolesnika (npp) u Kliničkom bolničkom centru Zagreb

Marija Gamulin ; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Milena Gnjidić ; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Deni Rkman ; School of Medicine, University of Zagreb, Zagreb, Croatia
Marko Bebek ; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia

Puni tekst: engleski, pdf (386 KB) str. 48-50 preuzimanja: 142* citiraj
APA 6th Edition
Gamulin, M., Gnjidić, M., Rkman, D. i Bebek, M. (2019). Treatment results of metastatic kidney cancer patients included in nivolumab - name patient program (npp) at University Hospital Center Zagreb. Libri Oncologici, 47 (2-3), 48-50. https://doi.org/10.20471/LO.2019.47.02-03.09
MLA 8th Edition
Gamulin, Marija, et al. "Treatment results of metastatic kidney cancer patients included in nivolumab - name patient program (npp) at University Hospital Center Zagreb." Libri Oncologici, vol. 47, br. 2-3, 2019, str. 48-50. https://doi.org/10.20471/LO.2019.47.02-03.09. Citirano 26.01.2021.
Chicago 17th Edition
Gamulin, Marija, Milena Gnjidić, Deni Rkman i Marko Bebek. "Treatment results of metastatic kidney cancer patients included in nivolumab - name patient program (npp) at University Hospital Center Zagreb." Libri Oncologici 47, br. 2-3 (2019): 48-50. https://doi.org/10.20471/LO.2019.47.02-03.09
Harvard
Gamulin, M., et al. (2019). 'Treatment results of metastatic kidney cancer patients included in nivolumab - name patient program (npp) at University Hospital Center Zagreb', Libri Oncologici, 47(2-3), str. 48-50. https://doi.org/10.20471/LO.2019.47.02-03.09
Vancouver
Gamulin M, Gnjidić M, Rkman D, Bebek M. Treatment results of metastatic kidney cancer patients included in nivolumab - name patient program (npp) at University Hospital Center Zagreb. Libri Oncologici [Internet]. 2019 [pristupljeno 26.01.2021.];47(2-3):48-50. https://doi.org/10.20471/LO.2019.47.02-03.09
IEEE
M. Gamulin, M. Gnjidić, D. Rkman i M. Bebek, "Treatment results of metastatic kidney cancer patients included in nivolumab - name patient program (npp) at University Hospital Center Zagreb", Libri Oncologici, vol.47, br. 2-3, str. 48-50, 2019. [Online]. https://doi.org/10.20471/LO.2019.47.02-03.09

Sažetak
Područje liječenja metastatskog raka bubrega (mRCC) je područje ubrzanog razvoja terapijskih mogućnosti. Nivolumab produljuje preživljenje bolesnika s metastatskim rakom bubrega uz dobar sigurnosni profil što je pokazano u kliničkoj studiji CheckMate025. Nivolumab u usporedbi s everolimusom produljuje preživljenje kod bolesnika sa mRCC uz povoljni sigurnosni profil lijeka. U ovoj analizi smo prikazali rezultate liječenja bolesnika nivolumabom u NPP u Kliničkom bolničkom centru Zagreb tijekom 2016. do 2018. 30% bolesnika ima preživljenje dulje od 30 mjeseci, a 16.6% je imalo kompletni odgovor na terapiju.

Ključne riječi
metastatski rak bubrega; nivolumab; druga linija liječenja

Hrčak ID: 233608

URI
https://hrcak.srce.hr/233608

[engleski]

Posjeta: 315 *